HEARTWISE - P-CARDIAC for Chinese: Population-based Study
Launched by THE UNIVERSITY OF HONG KONG · Feb 13, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The HEARTWISE - P-CARDIAC trial is studying a new way to predict the risk of heart disease in individuals, particularly among the Chinese population in Hong Kong. This study is focused on developing a tool called P-CARDIAC, which uses advanced technology known as Machine Learning to estimate the risk of having another heart-related event over the next ten years for people who have already experienced a heart issue. The goal is to see how accurate this new risk prediction model is when used in real-life medical settings, especially in clinics that specialize in heart health.
To participate in this study, individuals need to be between 18 and 80 years old and have visited specific medical clinics after experiencing a previous heart-related event, such as a heart attack or stroke. They should also be able to understand English or Traditional Chinese. Participants will have the chance to contribute to improving heart disease care while receiving information that may help their healthcare providers make better decisions for their treatment. It's important to note that people with certain conditions like dementia or severe physical impairments will not be eligible to join the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Individuals aged 18 - 80 years old who visit the medical or cardiology SOPC clinics at the Queen Mary Hospital (QMH), Pok Oi Hospital (POH), Kwong Wah Hospital (KWH), Princess Margaret Hospital (PMH), Queen Elizabeth Hospital (QEH), Tuen Mun Hospital (TMH) and experienced prior CVD event (such as peripheral artery diseases, coronary heart diseases, myocardial infarction, stroke, revascularization) before the scheduled SOPC clinic visit date are eligible to participate in this study. Participants will be also able to comprehend English or Traditional Chinese as well.
- Exclusion Criteria:
- • People with history of dementia, psychiatric diseases or physical impairment.
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Sze Ling Celine Chui, PhD
Principal Investigator
School of Nursing, The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported